800 patients with rare gene mutation tracked for pancreatic cancer risk

NCT ID NCT07413029

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 800 people who carry a mutation in the PRSS1 gene, which causes hereditary pancreatitis. Researchers will collect health data and questionnaires to track how often pancreatic cancer develops and how the disease progresses over time. The goal is to better understand the natural history of this rare condition and improve future care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could help doctors better predict pancreatic cancer risk in people with hereditary pancreatitis and improve monitoring guidelines.

What could go wrong

This is an observational study, not a treatment trial. It will not test any new drug or therapy, and results may take years to produce actionable insights.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY PANCREATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary chronic pancreatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • REBOURS

    RECRUITING

    Clichy-sous-Bois, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••